Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28258268 | 0.64 | MEN1 (0.36) | MEN1KMT2AKDM4EPOLBMAPT | |
| SCHEMBL28205887 | 0.64 | MEN1 (0.36) | MEN1KMT2AKDM4EPOLBMAPT | |
| SCHEMBL14342886 | 0.64 | MEN1 (0.36) | MEN1KMT2AKDM4EPOLBMAPT | |
| SCHEMBL30008978 | 0.63 | CRBN (0.38) | MEN1KMT2AKDM4EPOLBMAPT | |
| SCHEMBL9525717 | 0.62 | — | — | |
| SCHEMBL13042360 | 0.61 | KDM4E (0.42) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL9525791 | 0.61 | POLB (0.35) | MEN1KMT2AKDM4EPOLBMAPT | |
| SCHEMBL13100853 | 0.60 | MEN1 (0.44) | MEN1KMT2AKDM4EPOLBMAPT | |
| SCHEMBL16221368 | 0.60 | MEN1 (0.33) | MEN1KMT2AKDM4EPOLB | |
| SCHEMBL28196413 | 0.60 | MEN1 (0.33) | MEN1KMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9765078-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160185782-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9102678-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140046055-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140046055-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | MEN1 717/4885KMT2A 628/4885KDM4E 774/4885 |
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | MEN1 717/4885KMT2A 628/4885KDM4E 774/4885 |
| US-20160185782-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | MEN1 717/4885KMT2A 628/4885KDM4E 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.